Theriva Biologics, Inc. (TOVX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring on August 3, 2026, specifically the Company's 2026 Annual Meeting of Stockholders. Theriva Biologics, Inc. is a Nevada corporation with its principal executive offices in Rockville, Maryland, and its common stock trades on the NYSE American under the symbol "TOVX."
Key Financial Metrics
This filing is a corporate governance report and does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. No financial statements are included in this document.
Material Changes and Corporate Actions
Stockholders approved six proposals at the Annual Meeting:
- Director Elections: Four directors were elected: Jeffrey J. Kraws, Steven A. Shallcross, John Monahan, and Jeffrey Wolf.
- Stock Incentive Plan Amendment: Stockholders approved Amendment No. 4 to the 2020 Stock Incentive Plan, increasing the authorized share pool from 4,500,000 to 6,500,000 shares.
- Authorized Shares Increase: Stockholders approved an amendment to increase the number of authorized shares of common stock. The Board retains discretion on whether to file this charter amendment.
- Warrant Exercise Approval: Stockholders approved the issuance of common stock upon the exercise of outstanding warrants.
- Auditor Ratification: BDO USA, P.C. was ratified as the independent registered public accounting firm for the year ending December 31, 2026.
- Adjournment: A proposal to adjourn the meeting was approved but was not necessary as all other proposals passed.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding future financial guidance, operational outlook, or specific risk factors. The primary contingency noted is the Board's discretion to determine whether to effect the Charter Amendment to increase authorized shares, despite stockholder approval.
Key Facts for Investor Verification
- Verify the exact number of shares currently available for grant under the amended 2020 Stock Incentive Plan (capped at 6,500,000).
- Monitor future filings to confirm if the Board exercises its discretion to file the Charter Amendment increasing authorized shares.
- Review the Definitive Proxy Statement (filed June 29, 2026) for detailed terms regarding the warrant exercise approval and the specific terms of the new director elections.
- Note the significant number of broker non-votes (10,823,826) on director elections and the stock plan amendment, indicating a large portion of shares held in street name did not receive voting instructions.